AR008071A1 - Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienen - Google Patents
Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienenInfo
- Publication number
- AR008071A1 AR008071A1 ARP970103330A ARP970103330A AR008071A1 AR 008071 A1 AR008071 A1 AR 008071A1 AR P970103330 A ARP970103330 A AR P970103330A AR P970103330 A ARP970103330 A AR P970103330A AR 008071 A1 AR008071 A1 AR 008071A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- straight
- composition
- lower alkyl
- branched chain
- Prior art date
Links
- -1 AMINO Chemical class 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 229910052760 oxygen Chemical group 0.000 abstract 3
- 239000001301 oxygen Chemical group 0.000 abstract 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 abstract 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
Abarca los compuestos de la fórmula (I), en la cual uno de los X1, X2 y X3 es fórmula (II), y el resto de los miembros del grupo X1, X2 y X3 sonhidrógeno; y Q es nitrógeno u oxígeno; D está ausente cuando Q es oxígeno y cuando Q es nitrógeno, Des hidrógeno, alquilo inferior de cadena recta oramificada con 1 a 6 átomos de carbono, o puede estar unido con G para formar un anillo; E es O o H2; o y r son 0 o 1; G es alquilo inferior de cadenarecta o ramificada con 1 a 6 átomos de carbono, arilo, arilo sustituido con halógeno, alquilo inferior de cadena recta o ramificada con 1 a 6 átomos decarbono, heteroarilo seleccionado entre el grupo que consiste en 2-, 3- o 4- piridilo, 2-pirazilo, 2- o 3-tienilo, 2-pirazinilo, 2-, 3- o 4-quinolilo, 1-,3- o 4-isoquinolilo, 2-quinoxalilo, 3- o 4-cinolilo, heteroarilo sustituido con halógeno, hidroxi, alquilo inferior de cadena recta o ramificada con 1 a 6átomos de carbono, alcoxi inferior de cadena recta o ramificada con 1 a 6átomos de carbono; o está unido a D para formar un anillo; Ar es un grupoarilo preferentemente seleccionado entre el grupo que consiste en fenilo, 2- 3- o 4-piridilo, 2- o 3-tienilo, 2-, 4- o 5-pirimidilo, cada uno de los cualeses optativamente mono- o disustituido con halógeno, hidroxi, o alquilo inferior de cadena recta o ramificada con 1 a 6 átomos de carbono; B es azufre,oxígeno, N(R5) o C(R5)(R6); n es 1, 2 o 3; m es 2, 3 o 4; A y T son iguales o diferentes y representan hidrógeno, halógeno, hidroxi, alquilo inferior decadena recta o ramificada con 1 a 6 átomos de carbono, o alcoxi inferior de cadena recta o ramificada con 1 a 6 átomos de carbono; R1 y R2 son igualeso diferentes y representan hidrógeno, o alquilo inferior de cadena recta o ramificada con 1 a 6 átomos de carbono; R3 y R4 son iguales o diferentes y
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2229896P | 1996-07-23 | 1996-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008071A1 true AR008071A1 (es) | 1999-12-09 |
Family
ID=21808875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970103330A AR008071A1 (es) | 1996-07-23 | 1997-07-23 | Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienen |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6133265A (es) |
| EP (1) | EP0918761B1 (es) |
| JP (1) | JP2000515527A (es) |
| AR (1) | AR008071A1 (es) |
| AT (1) | ATE239002T1 (es) |
| AU (1) | AU3671897A (es) |
| CA (1) | CA2260983A1 (es) |
| CO (1) | CO4890841A1 (es) |
| DE (1) | DE69721541T2 (es) |
| DK (1) | DK0918761T3 (es) |
| ES (1) | ES2197354T3 (es) |
| HR (1) | HRP970412A2 (es) |
| ID (1) | ID17453A (es) |
| MA (1) | MA26435A1 (es) |
| PA (1) | PA8434601A1 (es) |
| PE (1) | PE1999A1 (es) |
| PT (1) | PT918761E (es) |
| TN (1) | TNSN97127A1 (es) |
| WO (1) | WO1998003494A1 (es) |
| ZA (1) | ZA976470B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT918761E (pt) * | 1996-07-23 | 2003-09-30 | Neurogen Corp | Algumas amidas e aminas substituidas com derivados de benzilamina uma nova classe de ligandos especificos do neuropeptido y1 |
| SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| EP1033366A3 (en) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amide derivatives useful as Neuropeptide Y (NPY) antagonists |
| WO2002006245A1 (en) * | 2000-07-05 | 2002-01-24 | Synaptic Pharmarceutical Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| MXPA03000174A (es) | 2000-07-06 | 2003-09-22 | Neurogen Corp | Ligandos de receptor de hormona concentradora de melanina. |
| WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
| US7514438B2 (en) | 2003-08-13 | 2009-04-07 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
| EP1680120A2 (en) | 2003-11-03 | 2006-07-19 | Probiodrug AG | Combinations useful for the treatment of neuronal disorders |
| EP1713780B1 (en) | 2004-02-05 | 2012-01-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| CN104788328B (zh) | 2004-06-24 | 2017-09-12 | 沃泰克斯药物股份有限公司 | Atp‑结合弹夹转运蛋白的调控剂 |
| EP1979367A2 (en) * | 2005-12-24 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Quinolin-4-one derivatives as modulators of abc transporters |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US7674811B2 (en) | 2006-03-14 | 2010-03-09 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| EP2117540A1 (en) | 2007-03-01 | 2009-11-18 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| SG10201504084QA (en) | 2009-03-20 | 2015-06-29 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| ES2481823T3 (es) | 2010-03-10 | 2014-07-31 | Probiodrug Ag | Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5) |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
| US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| WO2020172609A1 (en) * | 2019-02-21 | 2020-08-27 | Marquette University | Heterocyclic ligands of par1 and methods of use |
| US11130743B2 (en) | 2019-02-21 | 2021-09-28 | Marquette University | Heterocyclic ligands of PAR1 and methods of use |
| US11198699B2 (en) | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| TW202136219A (zh) * | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Trpml調節劑 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
| DK0395312T3 (da) * | 1989-04-22 | 1999-06-23 | Wyeth John & Brother Ltd | Piperazinderivater |
| US5900415A (en) * | 1994-11-07 | 1999-05-04 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
| IL117997A0 (en) * | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
| ATE230403T1 (de) * | 1996-07-23 | 2003-01-15 | Neurogen Corp | Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande |
| PT918761E (pt) * | 1996-07-23 | 2003-09-30 | Neurogen Corp | Algumas amidas e aminas substituidas com derivados de benzilamina uma nova classe de ligandos especificos do neuropeptido y1 |
| CA2260982A1 (en) * | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
-
1997
- 1997-07-18 PT PT97933564T patent/PT918761E/pt unknown
- 1997-07-18 AU AU36718/97A patent/AU3671897A/en not_active Abandoned
- 1997-07-18 DE DE69721541T patent/DE69721541T2/de not_active Expired - Fee Related
- 1997-07-18 EP EP97933564A patent/EP0918761B1/en not_active Expired - Lifetime
- 1997-07-18 JP JP10507143A patent/JP2000515527A/ja not_active Ceased
- 1997-07-18 ES ES97933564T patent/ES2197354T3/es not_active Expired - Lifetime
- 1997-07-18 WO PCT/US1997/012690 patent/WO1998003494A1/en not_active Ceased
- 1997-07-18 DK DK97933564T patent/DK0918761T3/da active
- 1997-07-18 US US08/897,046 patent/US6133265A/en not_active Expired - Fee Related
- 1997-07-18 AT AT97933564T patent/ATE239002T1/de not_active IP Right Cessation
- 1997-07-18 CA CA002260983A patent/CA2260983A1/en not_active Abandoned
- 1997-07-21 TN TNTNSN97127A patent/TNSN97127A1/fr unknown
- 1997-07-22 ZA ZA976470A patent/ZA976470B/xx unknown
- 1997-07-22 MA MA24730A patent/MA26435A1/fr unknown
- 1997-07-22 PE PE1997000652A patent/PE1999A1/es not_active Application Discontinuation
- 1997-07-23 PA PA19978434601A patent/PA8434601A1/es unknown
- 1997-07-23 AR ARP970103330A patent/AR008071A1/es unknown
- 1997-07-23 CO CO97041974A patent/CO4890841A1/es unknown
- 1997-07-23 ID IDP972554A patent/ID17453A/id unknown
- 1997-07-23 HR HR60/022,298A patent/HRP970412A2/hr not_active Application Discontinuation
-
2000
- 2000-08-08 US US09/633,055 patent/US6316617B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6133265A (en) | 2000-10-17 |
| ATE239002T1 (de) | 2003-05-15 |
| EP0918761A1 (en) | 1999-06-02 |
| PA8434601A1 (es) | 2000-05-24 |
| ID17453A (id) | 1998-01-08 |
| MA26435A1 (fr) | 2004-12-20 |
| US6316617B1 (en) | 2001-11-13 |
| DK0918761T3 (da) | 2003-08-25 |
| ZA976470B (en) | 1998-08-04 |
| DE69721541T2 (de) | 2004-03-18 |
| ES2197354T3 (es) | 2004-01-01 |
| WO1998003494A1 (en) | 1998-01-29 |
| CO4890841A1 (es) | 2000-02-28 |
| CA2260983A1 (en) | 1998-01-29 |
| AU3671897A (en) | 1998-02-10 |
| PT918761E (pt) | 2003-09-30 |
| TNSN97127A1 (fr) | 2005-03-15 |
| HRP970412A2 (en) | 1998-10-31 |
| EP0918761B1 (en) | 2003-05-02 |
| JP2000515527A (ja) | 2000-11-21 |
| DE69721541D1 (de) | 2003-06-05 |
| PE1999A1 (es) | 1999-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008071A1 (es) | Derivados de bencilamina amido- y aminosustituidos, metodo para su elaboracion, metodo para tratar o prevenir un trastorno fisiologico,medicamento que los contiene, uso de dichos compuestos para preparar medicamentos, profarmaco acilado y composicion farmaceutica que los contienen | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| DK0468470T3 (da) | Benzimidazoler, lægemidler indeholdende sådanne forbindelser og fremgangsmåde til deres fremstilling | |
| DE69507505D1 (de) | Anilin derivate | |
| AR028531A1 (es) | Compuestos organicos | |
| DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| BRPI0615111B8 (pt) | composto, composição farmacêutica, e, uso do composto | |
| TR200002671T2 (tr) | Bisiklo(2.2.1)Heptanlar ve ilgili bileşikler | |
| TR199801594A2 (xx) | CCR-3 resept�r antagonistleri. | |
| MXPA03011324A (es) | Preparacion de derivados de indolo o benzotienilo novedosa y uso de los mismos como inhibidores de proteina de preniltransferasa. | |
| PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
| HUP0302468A2 (hu) | Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
| MY116952A (en) | 4 substituted 2-carboxy-tetrahydroquinoline derivatives, pharmaceutical compositions comprising them and process for their preparation | |
| KR920002555A (ko) | 앤지오텐신 ii 수용체 길항질인 신규한 피리미딘 유도체, 그 제조방법 및 그를 포함하는 제약학적 조성물 | |
| CO5631438A2 (es) | Profarmacos de aminoacidos excitadores | |
| CY1115643T1 (el) | Διεγερτης νευρογενεσης ή θεραπευτικος παραγων νευροπαθειας που περιλαμβανει παραγωγα αλκυλ αιθερα ή αλας αυτου | |
| ATE161723T1 (de) | Arzneimittel zur verwendung bei der behandlung von parkinsonismus | |
| ATE455765T1 (de) | Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs | |
| UY25291A1 (es) | Procedimiento para la preparacion de isoquinolinas | |
| MX9203939A (es) | Derivados de hidroisoquinolina y composiciones farmaceuticas que los contienen. | |
| UA72919C2 (uk) | Ароматичні аміди, заміщені рибозою, спосіб їх одержання та фармацевтична композиція | |
| PE20001241A1 (es) | Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores | |
| Zacharie et al. | Design and Synthesis of New 1, 3, 5‐Trisubstituted Triazines for the Treatment of Cancer and Inflammation | |
| MY125037A (en) | 1,2,3,4 tetrahydroquinoline derivatives | |
| ATE273979T1 (de) | Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis |